

The logo for amoéba features a stylized circular emblem composed of three overlapping segments in blue, green, and yellow-green. A thin white horizontal line passes through the center of the emblem and the text.

amoéba

December 2025 | Investors Presentation

YOUR CONTACTS

A new dynamic driven by a united team with solid experience in international environments



Benoit VILLERS

Chairman of the Board of Directors

Since December 2023

- Member of senior management at Barry Callebaut and ADM for over 21 years



Jean-François DOUCET

CEO and Chief Financial Officer

Since May 2023

- 30 years' experience in management and finance
- Expertise in operations and strategy in the health and chemicals sectors, in commercial, industrial and international environments

A GREENTECH READY TO GO TO MARKET

Listed on Euronext Growth



BERNARD BLUM
AWARD 2025

Amoéba

Created in 2010, Amoéba is a French greentech specializing in the development of natural microbiological solutions based on the patented use of amoebas.

Some figures

2

Business focus:
biocontrol and
cosmetics

1

Development
platform

39

Patents

1


Production unit in
Chassieu (France)

27

Employees

€70m

Market
cap



RECENT CHRONOLOGY OF AMOÉBA

Change in governance at the end of 2023 and major advances since 2024

● 12/2023

Start of the transformation from an R&D company to an industrial and commercial enterprise

A renewed governance at the end of 2023 with the strengthened support of leading shareholder

● 2024

Cosmetics: efficacy proven by in vitro and clinical studies

● 2025

Biocontrol: on its way to market

Final approval of the biocontrol active substance by the European Commission

Authorisation for marketing obtained in the United States and pending in several European countries

Major distribution agreement (vines and vegetal crops) with **Koppert**, world leader in biocontrol

Signing of a Memorandum of Understanding (MoU) with **Syngenta** for cereal crops in Europe (November)

Cosmetics:

Agreement with Metron Technology (**OBV group**), a leading player in the Chinese cosmetics market, for the approval of the ingredient in China and its subsequent local marketing.

● 2026

Biocontrol and cosmetics



Expected start of sales, costs and investments under control

THE AMOEBA, DEFINITION AND SPECIFIC FEATURES

An amoeba

A naturally occurring unicellular microorganism found in all environmental compartments, particularly in humid environments, including the human body.

At present, there are over 17,000 known amoebae, but they remain unexploited, apart from the one for which Amoéba has developed patented applications.



Our amoeba

Origin

W. magna C2C Maky **bio sourced** in Aix-les-Bains thermal spring water, and **secure storage**

Innovation

The only company in the world capable of cultivating amoeba

Forms of use

Available in live or lysed form (fractionated amoeba)

Safety

- **Non-toxic** to humans
- **No ecotoxicity** demonstrated by tests and studies

Composition

- Contains 74% protein
- 50% of these proteins are unknown to the scientific world

Amoéba is the only company with patented applications and unique know-how to cultivate amoeba in sufficient volumes for industrial and commercial use, giving it a lead of at least 10 years.

TWO RANGES WITH A HIGH LEVEL OF MATURITY



Biocontrol AXPERA

9 years

Approval of the active substance in the EU and the US

Marketing Authorisation obtained in the USA and pending in several European countries

Agreement with Koppert

MoU with Syngenta

Cosmetics (anti-ageing)

3 years

Success of in vitro & clinical studies

INCI : worldwide except China

Signing of an agreement to obtain approval in China

Agreement with Metron to achieve distribution in China

Upcoming distribution plan for Europe

Development platform

Explore with partners the potentials to be exploited

Biostimulant, acne, wound healing, burn treatment, customised proteins...

AXPERA

A solution for the transition to sustainable agriculture is coming to market

Positive impact on agriculture



A highly competitive level of **performance**, demonstrated by over 600 field trials carried out in 19 countries.

A natural product that meets the requirements of sustainable agriculture for **a wide range of crops**:



- Under glass: tomatoes, cucumbers, etc.
- Open fields: vines, soya, etc.
- Public areas: golf courses, gardens ...



European **market** estimated at **€1.6 billion**, growing at +/- 10% / year

US market estimated at **€3 billion**, growing at +/- 15% / year.

Market launch for 2026

Regulatory



Final approval of the active substance by the European Commission in June 2025.

Marketing authorisation obtained in the United States. Marketing authorisation in France and other European countries expected in late 2025/early 2026.



Production

Gradual increase in production capacity (from 0.4 to 1 tonne) at Chassieu for commercial launch and through CDMO (production partnership) partners.



Distribution

Signing of a major distribution agreement with Koppert. Signing of a Memorandum of Understanding (MoU) with Syngenta.

THE IDEAL SOLUTION

To reduce the use of copper

Context

Copper is widely used to combat mildew, but its use poses environmental problems. From 2025, European regulations will continue to reduce the use of copper in agriculture.


Solution: AXPERA

- Example of the trial: combined with copper, Axpera reduces the amount of copper used by 83%, while maintaining the same efficacy as copper at full dose.
- Improved efficacy: Axpera, in combination with a chemical product, is **as effective as or even more effective**, than the chemical product alone.

This ability to be combined with other products is a major advantage when it comes to establishing commercial partnerships.

Distributors, who are often reluctant to simply replace a chemical product, can be convinced of the benefits of incorporating Axpera into their offering.

Efficacy on downy mildew for tomatoes



A POTENTIAL THAT IS ALREADY RECOGNISED

Amoéba's solution is highly acclaimed by winegrowers and biocontrol stakeholders

Combating downy mildew on vines in France

- 15 winegrowers have used **AXPERA in real conditions** in Bordeaux, Beaujolais, Côtes de Provence, Burgundy, and elsewhere.

François Bréhant, Technical Director at Château Léoville Barton: “*I am completely satisfied with the product and want to incorporate it into my treatment programme for years to come.*”

- **Confirmation of the effectiveness of AXPERA**, which delivers performance equivalent to that of a standard copper programme or a conventional programme.
- **AXPERA stands out as a practical, operational and environmentally friendly solution** in the face of a significantly stricter regulatory framework in France.

Winner of the Bernard Blum award



- **Awarded the Bernard Blum Gold Medal, the highest distinction granted for innovation in biocontrol.**
- It makes **AXPERA the most promising biocontrol solution of the year** in terms of protecting plants against fungal diseases.
- **Amoéba and AXPERA stood out for “their unique technology, the result of exemplary scientific, regulatory and agronomic research, which opens up unprecedented prospects for sustainable antifungal protection”.**

AMOÉBA x KOPPERT

Signing of a major distribution agreement with a global leader in biocontrol

Koppert

Mutual expertise and perfect synergy

€500 million in revenue, 2,750 employees, 30 subsidiaries, 20% annual growth, and distribution in more than 100 countries



Distribution

Exclusive distribution rights for Koppert for a period of 5 years

Vines and vegetables grown in greenhouses and open fields

18 European countries (France, the Netherlands, Germany, Italy, etc.) and the United States

Launch in 2026 and gradual rollout



Co-development of new products

Launch of discussions on the co-development of new biofungicide solutions for crops covered by the agreement

Significant growth opportunities in the coming years



Production

**Contract Development
Manufacturing Organizations*

Start of production at the Amoéba site in Chassieu (France)...

... and then scaling up with European CDMO* partners with whom we already work

AMOÉBA x SYNGENTA

Signing of a Memorandum of Understanding with Syngenta for cereal crops



A global leader in solutions for farmers

A Group specialising in crop protection and agricultural seeds

2024 revenue for the Agro division: €11.4 billion

Presence in nearly one hundred countries


Key aspects of the Memorandum of Understanding:

- ✓ **Develop and market innovative biofungicide solutions, based on Amoeba's biofungicide active ingredient, for the European cereal market.**
- ✓ **The initial objective will be to protect wheat crops against its main diseases** (yellow rust and septoria) in the European Union and the United Kingdom from 2028 onwards, and then to extend it to other cereals and field crops.
- ✓ Syngenta and Amoeba intend to sign a distribution agreement in spring 2026.

AND WE HAVE A POTENTIAL GAME-CHANGER...

Short-term development: Launch of a biofertilizer innovation

Promising initial results:



Corn model

With 100% treatment:

+16% length, **+42%** above-ground biomass and **+17%** root biomass

Salad model

With 100% treatment:

+46% length, **+111%** above-ground biomass and **+58%** root biomass

An additional market segment to optimize the use of industrial equipment

1 kg of active substance
=
5 liters of biocontrol
+
90 liters of biofertilizer

Simultaneously optimize revenue and production costs

Simplified regulatory process

Additional studies +/- 6 months

Launch potential: 2026–2027

THE POTENTIAL OF BIOCONTROL IS ONLY BEGINNING TO BE EXPLOITED



Agreement with Koppert:

Vineyards and vegetable crops in 18 European countries and the United States

MoU with Syngenta:

Wheat in the European Union and the United Kingdom

Discussions already in progress for:

- Co-development of new products with Koppert and Syngenta
- Development of other cereals and industrial crops with Syngenta
- Crops (fruit, etc.) and/or geographical areas (Asia, South America, etc.) not covered by the agreements
- Development potential for turf
- Potential for growth in the retail market


Biofertilizer

SKIN PROTECTION (ANTI-AGEING / ANTI-UV)


A recent and promising innovation with proven effects

October 2023 - Remarkable in-vitro studies

Visible restoration of skin structure



Mature untreated skin




Mature skin **treated**

Anti-ageing effect


	Filaggrin	Loricrin	Ki67	COL VII	HA (Dermis)	HA (Epidermis)	HA (Total skin)
Young skin	100	100	100	100	100	100	100
Aged skin	19	67	66	4	95	74	73
Treated aged skin	87	99	112	265	107	123	101

Anti-UV effect

Young skin irradiated with UV



Young skin **treated** and then irradiated with UV light



SKIN PROTECTION (ANTI-AGEING / ANTI-UV)


A recent and promising innovation with proven effects

May 2024 – the clinical study confirms excellent in-vitro tests

Results of clinical trials justifying very strong claims in the field of anti-ageing cosmetics:

- "improvement in the thickness of the dermis"
- "repairing effect on the superficial dermis"
- "improved dermal texture"
- "improved skin density"
- "improved skin firmness and radiance"
- "improved skin texture and elasticity"
- "anti-wrinkle"

Wrinkle reduction after 28 days



Photos of the Institute for Clinical Expertise (IEC) in Lyon, taken with the professional camera opposite:



Newtone Technologies

AMOÉBA x ORIENTAL BEAUTY VALLEY

Signature of a contract with Metron Technology, a subsidiary of China's leading cosmetics company

A strategic player in cosmetics in China

The Oriental Beauty Valley group is an industrial centre of excellence based in Shanghai, supported by the Chinese authorities.

It brings together more than 1,000 companies (including L'Oréal and Shiseido) in the field of beauty and well-being.



Two major objectives

- ✓ On the regulatory front: approval of Amoéba's cosmetic ingredient in China (the world's 2nd largest cosmetics market, estimated at 85 billion euros)
- ✓ On the commercial front: distribution agreement with Chinese cosmetics groups

If approved in China, Amoéba's cosmetic ingredient could then be used worldwide, paving the way for future collaborations with international groups wanting to use the same formulas throughout the world.

SKIN PROTECTION (ANTI-AGEING / ANTI-UV)

A recent and promising innovation with proven effects

2023

Brevet

Filing of a patent to protect the use of amoeba as a cosmetic ingredient

In vitro studies

2024

INCI

Inclusion of our cosmetic ingredient on the **INCI*** (International Nomenclature of Cosmetics Ingredients) list of products, which means it can be marketed without further approval

Clinical study

** INCI: International Nomenclature Cosmetics Ingredients*

2025

Label Cosmos approved

Label certifying the natural origin and eco-friendly ingredient

Contract Metron – OBV

Registration and distribution in China

2025-26

Development

- Business development agreement(s)
- Product testing and development : (formulation testing, range creation, etc.)
- Expansion of our active ingredient range
- Registration in China

2026-27

Production & commercialisation

Production and marketing of the ingredient

A MAJOR REINFORCEMENT FOR THE AMOÉBA BOARD

A personality with multiple areas of expertise in the cosmetics and beauty industry

Charlotte FRANCERIES



A major player in the world of cosmetics and communication

✓ **25 years with the L'Oréal group**

- International Marketing Director Vichy
- International Marketing Director L'Oréal Paris skin care
- Biotherm International Managing Director
- Managing Director France Yves Saint Laurent Beauté
- International Managing Director Roger et Gallet
- Managing Director International L'Oréal Paris

✓ **7 years with the French subsidiary of the McCann Group (one of the world's leading advertising and communications agencies)**

- Currently President of the French agency
- Worldwide Global Account Manager L'Oréal

A COMPAGNY WITH STRONG SUPPORT

Board of Directors



Benoit VILLERS

Chairman



Valérie LORENTZ-POINSOT

Former CEO Laboratoires
Boiron



Charlotte FRANCERIES

President of McCann France
Former top management L'Oréal



Patrice SELLES

Former Executive at Syngenta
Former CEO Biotalys



Quentin HUA

Laboratoires Boiron



Jean-Marc PETAT

Former Executive of BASF
Agro-France




Valérie FILIATRE

Former Deputy General
Manager of Amoéba

Shareholder structure following the capital increase

(as of 23 July 2025)



Market capitalisation: €70m

SHAREHOLDER'S NOTEBOOK

- **Share price on 28/11/2025:**
€0.965

- **Number of shares:**
68,919,250 (24 July 2025)

- **Market capitalisation:**
€70 million

- **Average daily volume**
380,000 shares traded per day
in 2025

(+186% compared to 2024)



4 research firms monitor Amoéba:



Buy



Buy



Buy



Hold

Average target price : €1.70

(FactSet consensus)

WHY INVEST ...

The only company in the world dedicated to amoeba culture

Unique Technological Expertise

- ✓ The only company capable of cultivating an amoeba on an industrial scale.
- ✓ Exclusive technology enabling the amoeba to live and reproduce.

Global Exclusivity

- ✓ The only private company in the world leveraging the positive applications of amoebas.
- ✓ An innovative alternative in a field where hundreds of companies focus on proteins, algae, and other resources...

Leadership Position

- ✓ Competitive advantages driven by unique specialization and expertise.
- ✓ Several years ahead of potential competitors.

Growth Potential

- ✓ Expanding fields from agriculture to cosmetics, with potential openings in other sectors, such as medical applications.



Amoéba



amoeba-nature.com



amoeba@actus.fr

DISCLAIMER

References herein to this presentation (the “Presentation”) shall mean and include this document, any oral presentation accompanying this document provided by Amoeba SA (the “Company”), any question-and-answer session following that oral presentation and any further information that may be made available in connection with the subject matter contained herein.

This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the multilateral trading facility of Euronext Growth, including, in particular, the risk factors set out in the universal registration document (the “URD”) filed with the French Financial Markets Authority (Autorité des marchés financiers) (the “AMF”) on April 18, 2023 under number D.23-0296, and in any other periodic report, which are available free of charge on the websites of the Company (<https://amoeba-nature.com>) and the AMF (www.amf-france.org). Information and other data appearing in such publications, and certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures, amounts or percentages.

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this Presentation, or its use for any purpose, and no reliance should be placed on any information or opinions contained herein. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular, this document contains information on the Company’s markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company’s own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised or amended, and thus such information is subject to change at any time. Neither the Company, its subsidiaries, directors, officers, employees, agents, affiliates nor its advisors, nor any other person is under any obligation to update the information, statements or opinions contained in this Presentation. Nothing contained in this Presentation is or should be relied upon as a promise or representation as to the future.

All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties, and other factors, could adversely affect the outcome of the forward-looking statements, and actual results could differ materially from those contemplated in the statements. As a result, you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation.

This Presentation does not constitute or form any part of any offer to sell, or the solicitation of an offer to buy or subscribe for, any shares or securities in the Company, in the United States or in any other jurisdiction.

All persons accessing this document are deemed to agree and comply with all the limitations and restrictions set out above.